(Matrix Metalloprotease-9) Activity Reduces Cellular Inflammation and Restores Function of Transplanted Pancreatic Islets
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metalloproteinase-9 and Chemotaxis Inflammatory Cell Production of Matrix AQARSAASKVKVSMKF, Induces 5, Α a Site on Laminin
A Site on Laminin α5, AQARSAASKVKVSMKF, Induces Inflammatory Cell Production of Matrix Metalloproteinase-9 and Chemotaxis This information is current as of September 25, 2021. Tracy L. Adair-Kirk, Jeffrey J. Atkinson, Thomas J. Broekelmann, Masayuki Doi, Karl Tryggvason, Jeffrey H. Miner, Robert P. Mecham and Robert M. Senior J Immunol 2003; 171:398-406; ; doi: 10.4049/jimmunol.171.1.398 Downloaded from http://www.jimmunol.org/content/171/1/398 References This article cites 64 articles, 24 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/171/1/398.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 25, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology A Site on Laminin ␣5, AQARSAASKVKVSMKF, Induces Inflammatory Cell Production of Matrix Metalloproteinase-9 and Chemotaxis1 Tracy L. Adair-Kirk,* Jeffrey J. Atkinson,* Thomas J. -
High Serum Levels of Matrix Metalloproteinase-9 and Matrix
Imaging, Diagnosis, Prognosis High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1Are Associated with Rapid Progression in Patients with Metastatic Melanoma Johanna Nikkola,1, 3 PiaVihinen,1, 3 Meri-SiskoVuoristo,4 Pirkko Kellokumpu-Lehtinen,4 Veli-Matti Ka« ha« ri,2 and Seppo Pyrho« nen1, 3 Abstract Purpose: Matrixmetalloproteinases (MMP) are proteolytic enzymes that play an important role in various aspects of cancer progression. In the present work, we have studied the prognostic significance of serum levels of gelatinase B (MMP-9), collagenase-1 (MMP-1), and collagenase- 3 (MMP-13) in patients with advanced melanoma. Experimental Design:Total pretreatment serum levels of MMP-9 in 71patients and MMP-1and MMP-13 in 48 patients were determined by an assay system based on ELISA. Total MMP levels were also assessed in eight healthy controls. The active and latent forms of MMPs were defined by usingWestern blot analysis and gelatin zymography. Results: Patients with high serum levels of MMP-9 (z376.6 ng/mL; n = 19) had significantly poorer overall survival (OS) than patients with lower serum MMP-9 levels (n =52;medianOS, 29.1versus 45.2 months; P = 0.033). High MMP-9 levels were also associated with visceral or bone metastasis (P = 0.027), elevated serum alkaline phosphatase level (P = 0.0009), and presence of liver metastases (P =0.032).SerumlevelsofMMP-1andMMP-13didnotcorrelate with OS. MMP-1and MMP-9 were found mainly in latent forms in serum, whereas the majority of MMP-13 in serum was active (48 kDa) form. MMP-13 was found more often in active form in patients (mean, 99% of the total MMP-13 level) than in controls (mean, 84% of the total MMP-13 level; P < 0.0001). -
9/Gelatinase B Reduce NK Cell-Mediated Cytotoxicity
in vivo 22 : 593-598 (2008) A High Concentration of MMP-2/ Gelatinase A and MMP- 9/ Gelatinase B Reduce NK Cell-mediated Cytotoxicity against an Oral Squamous Cell Carcinoma Cell Line BU-KYU LEE 1, MI-JUNG KIM 2, HA-SOON JANG 1, HEE-RAN LEE 2, KANG-MIN AHN 1, JONG-HO LEE 3, PILL-HOON CHOUNG 3 and MYUNG-JIN KIM 3 Departments of 1Oral and Maxillofacial Surgery and 2Cell Biology, Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, Ulsan University, Songpa-ku, 138-040, Seoul; 3Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University, Jongno-ku, 110-768, Seoul, Korea Abstract. Background: Recent studies have shown that advanced state of the disease had generally reduced host matrix metalloproteinases (MMPs) from tumors influence the immune function (3, 4). Nevertheless, the exact role of host immune system to reduce antitumor activity. The aim of immune cells, and of the immune system in general, in the this study was to examine the influence of MMP-2 and development of OSCC and in tumor progression remains MMP-9 on the natural killer (NK) cell. Materials and ambiguous. While the initiation of the process of Methods: NK cells were pretreated with either MMP-2 or tumorigenesis is clearly linked to carcinogens ( i.e. tobacco MMP-9 in the experimental group but not in the control or alcohol), its progression through a series of discrete group. NK cell cytotoxicity against oral squamous cell genetic changes results in the emergence of a tumor that is carcinoma cells (OSCC) were examined using the [Cr 51 ] resistant to immune effector cells (5, 6). -
An Adverse Role for Matrix Metalloproteinase 12 After Spinal Cord Injury in Mice
The Journal of Neuroscience, November 5, 2003 • 23(31):10107–10115 • 10107 Development/Plasticity/Repair An Adverse Role for Matrix Metalloproteinase 12 after Spinal Cord Injury in Mice Jennifer E. A. Wells,1 Tiffany K. Rice,1 Robert K. Nuttall,3 Dylan R. Edwards,3 Hakima Zekki,4 Serge Rivest,4 V. Wee Yong1,2 Departments of 1Clinical Neurosciences and 2Oncology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada, 3School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, United Kingdom, and 4Laboratory of Molecular Endocrinology and Department of Anatomy and Physiology, Laval University, Quebec, Quebec G1V 4G2, Canada We investigated the role of matrix metalloproteinases (MMPs) in acute spinal cord injury (SCI). Transcripts encoding 22 of the 23 known mammalian MMPs were measured in the mouse spinal cord at various time points after injury. Although there were significant changes in the expression levels of multiple MMPs, MMP-12 was increased 189-fold over normal levels, the highest of all MMPs examined. To evaluate the role of MMP-12 in SCI, spinal cord compression was performed in wild-type (WT) and MMP-12 null mice. Behavioral analyses were conducted for 4 weeks using the Basso–Beattie–Bresnahan (BBB) locomotor rating scale as well as the inclined plane test. The results show that MMP-12 null mice exhibited significantly improved functional recovery compared with WT controls. Twenty-eight days after injury, the BBB score in the MMP-12 group was 7, representing extensive movement of all three hindlimb joints, compared with 4 in the WT group, representing only slight movement of these joints. -
Virulence Characteristics of Meca-Positive Multidrug-Resistant Clinical Coagulase-Negative Staphylococci
microorganisms Article Virulence Characteristics of mecA-Positive Multidrug-Resistant Clinical Coagulase-Negative Staphylococci Jung-Whan Chon 1, Un Jung Lee 2, Ryan Bensen 3, Stephanie West 4, Angel Paredes 5, Jinhee Lim 5, Saeed Khan 1, Mark E. Hart 1,6, K. Scott Phillips 7 and Kidon Sung 1,* 1 Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA; [email protected] (J.-W.C.); [email protected] (S.K.); [email protected] (M.E.H.) 2 Division of Cardiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; [email protected] 3 Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA; [email protected] 4 Department of Animal Science, University of Arkansas, Fayetteville, AR 72701, USA; [email protected] 5 NCTR-ORA Nanotechnology Core Facility, US Food and Drug Administration, Jefferson, AR 72079, USA; [email protected] (A.P.); [email protected] (J.L.) 6 Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA 7 Division of Biology, Chemistry, and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-(870)-543-7527 Received: 20 March 2020; Accepted: 29 April 2020; Published: 1 May 2020 Abstract: Coagulase-negative staphylococci (CoNS) are an important group of opportunistic pathogenic microorganisms that cause infections in hospital settings and are generally resistant to many antimicrobial agents. -
Unique Regulation of the Matrix Metalloproteinase, Gelatinase B
Unique Regulation of the Matrix Metalloproteinase, Gelatinase B M. Elizabeth Fini, Marie T. Girard, Masao Matsubara, and John D. Bartlett Purpose. The matrix metalloproteinase (MMP), gelatinase B, is expressed by both corneal cell types found at the epithelial-stromal tissue interface, the site of basement membrane repair in the healing cornea. This study investigates the relative regulation of gelatinase B compared to other MMPs in response to agents related to those found in the corneal repair environment or in corneal ulcers. Methods. A culture model of corneal cells isolated from rabbit was used. Results. Gelatinase B is the major MMP expressed by corneal epithelial cells, whereas stromal fibroblasts produce gelatinase B along with three other MMPs: collagenase, stromelysin, and gelatinase A. Phorbol-12-myristate 13-acetate (PMA) stimulates gelatinase B mRNA and pro- tein synthesis by corneal cells, which is similar to its effect on the other MMPs. Stimulation occurs, at least partially, at the transcriptional level. PMA-stimulated MMP expression follows biphasic kinetics, with the major effect on collagenase, stromelysin, and gelatinase A occurring during the late component. In contrast, the major gelatinase B response occurs during the early component. Transforming growth factor-beta (TGF-/?) has no effect on constitutive expression of gelatinase B by fibroblasts; however, expression stimulated by PMA is enhanced. In contrast, constitutive expression of collagenase and stromelysin is inhibited by TGF-/3. However, in the presence of PMA, the initial inhibitory effect of TGF-/3 is reversed after treatment. Conclusion. Gelatinase B expression is regulated differently from other corneal MMPs. This provides a mechanism for control of basement membrane repair independent of repair processes in the stroma. -
Reduced Angiogenesis and Tumor Progression in Gelatinase A-Deficient Mice1
(CANCER RESEARCH.«. 11)48-1(151. March 1. 1998] Reduced Angiogenesis and Tumor Progression in Gelatinase A-deficient Mice1 Takeshi höh,2Masatoshi Tanioka, Hiroshi Yoshida, Takayuki Yoshioka, Hirofumi Nishimoto, and Shigeyoshi Itohara Shionogi Institute for Medical Science. Shionogi & Co., Lid. IT. /.. M. T., H. N.¡and Discovery Research Laboratories II, Shionogi & Co., Ltd. [H. Y., T. Y.J, Fukushima-ku, Osaka 553. and Institute for Virus Research. Kyoto University. Syogo-in. Sakyo-ku, Kyoto 606-01 ¡S././. Japan ABSTRACT normalities and are fertile, thus offering a useful system for assessing the specific role of gelatinase A in tumor progression. We show here Matrix proteolysis is thought to play a crucial role in several stages of that the rates of angiogenesis and experimental tumor growth and tumor progression, including angiogenesis, and the invasion and metas metastasis are markedly reduced in these gelatinase A-deficient mice. tasis of tumor cells. We investigated the specific role of gelatinase A This is the first direct evidence that host-derived gelatinase A plays a (matrix metalloproteinase 2) on these events using gelatinase A-deficient mice. In these mice, tumor-induced angiogenesis was suppressed accord specific role in angiogenesis and tumor progression in vivo. ing to dorsal air sac assay. When B16-BL6 melanoma cells or Lewis lung carcinoma cells were implanted intradermally, the tumor volumes at 3 MATERIALS AND METHODS weeks after implantation in the gelatinase A-deficient mice decreased by 39% for B16-BL6 melanoma and by 24% for Lewis lung carcinoma Animals. The generation of gelatinase A-deficient mice was described (P < 0.03 for each tumor). -
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48 -
During Acute Lung Injury Extracellular Matrix Protein Degradation Of
ADAM9 Is a Novel Product of Polymorphonuclear Neutrophils: Regulation of Expression and Contributions to Extracellular Matrix Protein Degradation This information is current as during Acute Lung Injury of September 30, 2021. Robin Roychaudhuri, Anja H. Hergrueter, Francesca Polverino, Maria E. Laucho-Contreras, Kushagra Gupta, Niels Borregaard and Caroline A. Owen J Immunol 2014; 193:2469-2482; Prepublished online 25 Downloaded from July 2014; doi: 10.4049/jimmunol.1303370 http://www.jimmunol.org/content/193/5/2469 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2014/07/25/jimmunol.130337 Material 0.DCSupplemental References This article cites 66 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/193/5/2469.full#ref-list-1 by guest on September 30, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology ADAM9 Is a Novel Product of Polymorphonuclear Neutrophils: Regulation of Expression and Contributions to Extracellular Matrix Protein Degradation during Acute Lung Injury Robin Roychaudhuri,*,1 Anja H. -
Increased TIMP-3 Expression Alters the Cellular Secretome Through Dual
www.nature.com/scientificreports OPEN Increased TIMP-3 expression alters the cellular secretome through dual inhibition of the metalloprotease Received: 21 September 2017 Accepted: 6 August 2018 ADAM10 and ligand-binding of the Published: xx xx xxxx LRP-1 receptor Simone D. Scilabra1,2, Martina Pigoni1, Veronica Pravatá 1, Tobias Schätzl1, Stephan A. Müller1, Linda Troeberg 3 & Stefan F. Lichtenthaler1,2,4,5 The tissue inhibitor of metalloproteinases-3 (TIMP-3) is a major regulator of extracellular matrix turnover and protein shedding by inhibiting diferent classes of metalloproteinases, including disintegrin metalloproteinases (ADAMs). Tissue bioavailability of TIMP-3 is regulated by the endocytic receptor low-density-lipoprotein receptor-related protein-1 (LRP-1). TIMP-3 plays protective roles in disease. Thus, diferent approaches have been developed aiming to increase TIMP-3 bioavailability, yet overall efects of increased TIMP-3 in vivo have not been investigated. Herein, by using unbiased mass-spectrometry we demonstrate that TIMP-3-overexpression in HEK293 cells has a dual efect on shedding of transmembrane proteins and turnover of soluble proteins. Several membrane proteins showing reduced shedding are known as ADAM10 substrates, suggesting that exogenous TIMP-3 preferentially inhibits ADAM10 in HEK293 cells. Additionally identifed shed membrane proteins may be novel ADAM10 substrate candidates. TIMP-3-overexpression also increased extracellular levels of several soluble proteins, including TIMP-1, MIF and SPARC. Levels of these proteins similarly increased upon LRP-1 inactivation, suggesting that TIMP-3 increases soluble protein levels by competing for their binding to LRP-1 and their subsequent internalization. In conclusion, our study reveals that increased levels of TIMP-3 induce substantial modifcations in the cellular secretome and that TIMP-3-based therapies may potentially provoke undesired, dysregulated functions of ADAM10 and LRP-1. -
Towards Third Generation Matrix Metalloproteinase Inhibitors for Cancer Therapy
British Journal of Cancer (2006) 94, 941 – 946 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00 www.bjcancer.com Minireview Towards third generation matrix metalloproteinase inhibitors for cancer therapy ,1 1 CM Overall* and O Kleifeld 1CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, Biochemistry & Molecular Biology, The UBC Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3 The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection. British Journal of Cancer (2006) 94, 941–946. doi:10.1038/sj.bjc.6603043 www.bjcancer.com Published online 14 March 2006 & 2006 Cancer Research UK Keywords: target validation; antiproteolytic drug; cancer therapy; drug design; zinc chelation Twenty five years ago, the therapeutic strategy of controlling avenues for the therapeutic control of cancer. Conversely, stromal cancer by broadly targeting collagenase (matrix metalloproteinase cells harness the beneficial actions of MMPs in tissue homeostasis (MMP)1), stromelysin-1 (MMP3), and gelatinase A (MMP2), the and innate immunity for host resistance against cancer (Overall three then known MMPs, was founded on reducing degradation of and Kleifeld, 2006). All MMPs exhibit some of these functions, basement membrane and extracellular matrix proteins by cancer but MMPs -3, -8 and -9 have activities so important that when cells in metastasis and angiogenesis (Liotta et al, 1980; Hodgson, genetically knocked out, this leads to enhanced tumorigenesis and 1995). -
Expression and Regulation of Matrix Metalloproteinase-12 in Experimental Autoimmune Encephalomyelitis and by Bone Marrow Derived
Journal of Neuroimmunology 199 (2008) 24–34 www.elsevier.com/locate/jneuroim Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro ⁎ Angelika Goncalves DaSilva, V. Wee Yong Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Department of Oncology, University of Calgary, Calgary, Alberta, Canada Received 3 November 2007; received in revised form 2 April 2008; accepted 21 April 2008 Abstract Several matrix metalloproteinase (MMP) members contribute to pathology in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). As the role of MMP-12 in EAE has been understudied, we examined its expression in EAE and in vitro. MMP-12 transcripts increased with EAE, and protein was localized to a subset of macrophages/microglia. The temporal expression of MMP-12 largely corresponded to that of cytokines, and we demonstrate that IL-1β and TNF-α promoted MMP-12 expression in cultured macrophages. We postulate that cytokine — MMP-12 interactions are important in the disease process of EAE. © 2008 Elsevier B.V. All rights reserved. Keywords: Cytokines; Metalloproteinases; Experimental autoimmune encephalomyelitis; Neuroinflammation; Proteases 1. Introduction cerebral vascular vessels (Cossins et al., 1997; Kouwenhoven et al., 2002; Agrawal et al., 2006; Toft-Hansen et al., 2006). Multiple sclerosis (MS) is an autoimmune neurological Besides participating in BBB breakdown, MMPs can also disease primarily affecting young adults. Experimental auto- produce demyelination and axonal injury, promote neuroin- immune encephalomyelitis (EAE), a commonly used animal flammation via the proteolysis of zymogens, and participate in model of MS, has provided many clues to the general mediating cell death (Kieseier et al., 1999; Yong et al., 2001; understanding of MS, but the etiology of the disease remains Opdenakker et al., 2003).